Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 524

1.
2.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
3.

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

Johnston SR, Leary A.

Drugs Today (Barc). 2006 Jul;42(7):441-53. Review.

PMID:
16894399
4.

Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.

Paul B, Trovato JA, Thompson J.

Am J Health Syst Pharm. 2008 Sep 15;65(18):1703-10. doi: 10.2146/ajhp070646. Review.

PMID:
18768996
5.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D.

N Engl J Med. 2006 Dec 28;355(26):2733-43. Erratum in: N Engl J Med. 2007 Apr 5;356(14):1487.

6.

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

Ito Y, Tokudome N, Sugihara T, Takahashi S, Hatake K.

Breast Cancer. 2007;14(2):156-62. Review.

7.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL.

J Clin Oncol. 2005 Aug 10;23(23):5305-13.

PMID:
15955900
8.

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.

Montemurro F, Valabrega G, Aglietta M.

Expert Opin Biol Ther. 2007 Feb;7(2):257-68. Review.

PMID:
17250463
9.

Lapatinib and ixabepilone for the treatment of metastatic breast cancer.

Halterman PA.

Pharmacotherapy. 2008 Oct;28(10):1255-66. doi: 10.1592/phco.28.10.1255. Review.

PMID:
18823221
10.

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.

Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL.

J Clin Oncol. 2008 Mar 1;26(7):1066-72. doi: 10.1200/JCO.2007.13.9949.

PMID:
18212337
12.

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.

Chen FL, Xia W, Spector NL.

Clin Cancer Res. 2008 Nov 1;14(21):6730-4. doi: 10.1158/1078-0432.CCR-08-0581. Review.

13.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734.

PMID:
19786658
14.

An overview of HER-targeted therapy with lapatinib in breast cancer.

McArthur H.

Adv Ther. 2009 Mar;26(3):263-71. doi: 10.1007/s12325-009-0012-y. Review.

PMID:
19365626
15.

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.

Nelson MH, Dolder CR.

Ann Pharmacother. 2006 Feb;40(2):261-9. Review.

PMID:
16418322
16.

Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

Cameron DA, Stein S.

Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Review.

PMID:
18594499
17.

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE.

Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0.

PMID:
18188694
18.

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.

Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, Gilmer TM.

Cell Prolif. 2007 Aug;40(4):580-94.

PMID:
17635524
19.

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.

Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI.

Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52.

PMID:
14751502
20.

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.

Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels JP, Pétavy F, Gore M, Schöffski P, El-Hariry I.

J Clin Oncol. 2008 May 10;26(14):2285-91. doi: 10.1200/JCO.2007.14.5029.

PMID:
18467719

Supplemental Content

Support Center